A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety profile of SGN-35 alone and in combination with
gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of
patients.